humulene and Heart-Valve-Diseases

In the group of medication acting on the dopaminergic system the transdermal application of a dopamine agonist (Rotigotine) and a new MAO B inhibitor (Rasigiline) are receiving most attention. With some concern we had to learn that pergolide, a potent dopamine agonist, may be the cause of clinically relevant valvulopathies. Our possibilities to act on non-dopaminergic deficits is still very limited. The studies demonstrating a positive effect of cholinesterase inhibitors on cognitive decline are at least a positive signal.

Topics: Antiparkinson Agents; Cannabis; Cholinesterase Inhibitors; Controlled Clinical Trials as Topic; Dopamine Agonists; Heart Valve Diseases; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Pergolide; Phenylcarbamates; Placebos; Rivastigmine; Time Factors